SGLT2i Therapy in Islet Transplantation (SIT)

Part of paid clinical trials in Minneapolis, Minnesota.

Sponsor
University of Minnesota
Study ID
NCT07228195
Phase
PHASE4
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Diabetes
  • Partial Islet Function
  • TPIAT

Eligibility Criteria

Sex
ALL
Age
18 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

  • Empagliflozin 25 MG Oral Tablet — DRUG
    Empagliflozin, which is sold under the name of Jardiance, is FDA approved for patients 10 years of age and older to improve glycemic control in type 2 diabetes.
  • Empagliflozin 10 MG Oral Tablet [Jardiance] — DRUG
    Empagliflozin, which is sold under the name of Jardiance, is FDA approved for patients 10 years of age and older to improve glycemic control in type 2 diabetes.

Study Details

This pilot clinical trial is designed to gather preliminary data on the efficacy and safety of empagliflozin, a diabetes drug in the sodium-glucose cotransporter 2 inhibitor (SGLT2i) class, in islet autotransplant recipients who have partial islet function.

Key Dates

Start date
Jul 15, 2026
Status verified
May 2026
Primary completion
Dec 1, 2028
Completion
Dec 1, 2028

Study Design

Enrollment
40 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • No Intervention: No Medication x 3 months, then 25 mg Empagliflozin x 3 months
  • Active Comparator: Empagliflozin 10 mg x 3 months, then 25 mg Empagliflozin x 3 months
  • Active Comparator: Empagliflozin 25 mg x 6 months

Primary Outcome Measure

Time In Range (TIR) 70- 180 mg/dL [ Time Frame: Month 3 ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
University of MinnesotaMinneapolisMinnesota55455
Peggy Ptacek

Find similar trials in Minneapolis, MN

Related Studies